Provided by Tiger Fintech (Singapore) Pte. Ltd.

Beam Therapeutics, Inc.

21.54
+0.51002.43%
Pre-market: 21.720.1800+0.84%08:29 EDT
Volume:1.94M
Turnover:41.54M
Market Cap:2.17B
PE:-4.66
High:21.76
Open:21.41
Low:20.86
Close:21.03
Loading ...

AI Biotech Stocks Shined. Recursion Soared 10%; Absci Up 7%; Crispr Up 6%; Beam And Ginkgo Up 3%

Tiger Newspress
·
21 Jul

Cathie Wood’s ARK Investment buys 659K shares of Beam Therapeutics today

TIPRANKS
·
08 Jul

Chief Medical Officer Simon Amy Reports Disposal of Common Shares of Beam Therapeutics Inc

Reuters
·
04 Jul

Beam Therapeutics Acquires Early-Stage Life Sciences Firm

TIPRANKS
·
04 Jul

BRIEF-Beam Therapeutics Buys Early-Stage Life Sciences Company

Reuters
·
04 Jul

Beam Therapeutics Inc - Potential Additional Payments up to $89 Mln - SEC Filing

THOMSON REUTERS
·
04 Jul

Beam Therapeutics Inc - Buys Early-Stage Life Sciences Company - SEC Filing

THOMSON REUTERS
·
04 Jul

Beam Therapeutics Inc. Issues 403,128 Shares as Upfront Payment and Announces Potential Additional Milestone Shares Worth Up to $89 Million in Acquisition Deal

Reuters
·
04 Jul

Beam Therapeutics (BEAM) Gets a Buy from Wedbush

TIPRANKS
·
16 Jun

Analysts Have Conflicting Sentiments on These Healthcare Companies: Merus (MRUS) and Beam Therapeutics (BEAM)

TIPRANKS
·
16 Jun

Beam Therapeutics’ BEAM-101: Promising Advancements in Sickle Cell Disease Treatment with Strong Phase 1/2 Trial Results

TIPRANKS
·
13 Jun

Beam Therapeutics Announces Promising New Data from BEACON Phase 1/2 Trial of BEAM-101 for Sickle Cell Disease at EHA 2025 Congress

Reuters
·
13 Jun

Beam Therapeutics Inc - Enrollment Complete in Beacon Trial, 30 Patients Expected by Mid-2025

THOMSON REUTERS
·
13 Jun

Beam Therapeutics Announces New Data From Beacon Phase 1/2 Clinical Trial of Beam-101 Supporting Differentiated Profile in Sickle Cell Disease (Scd) at European Hematology Association (Eha) 2025 Congress

THOMSON REUTERS
·
13 Jun

Beam Therapeutics Confirms Key Decisions at Annual Meeting

TIPRANKS
·
07 Jun

Bernstein Reaffirms Their Buy Rating on Beam Therapeutics (BEAM)

TIPRANKS
·
06 Jun

BEAM Up on FDA's Orphan Drug Status for Gene-Editing Therapy

Zacks
·
04 Jun

Can CRISPR Build on Casgevy's Success With Its In Vivo Pipeline?

Zacks
·
04 Jun

BUZZ-U.S. STOCKS ON THE MOVE-Guardant Health, Hewlett Packard Enterprise, Venture Global

Reuters
·
04 Jun

Roadzen’s DrivebuddyAI Awarded Patent for Real-Time Driver Drowsiness Detection — Crosses 1.8 Billion Kilometers of Real-World AI Driving Data

GlobeNewswire
·
03 Jun